These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9332680)

  • 21. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
    Spielmann M; Llombart A; Zelek L; Sverdlin R; Rixe O; Le Cesne A
    Ann Oncol; 1999 Dec; 10(12):1457-60. PubMed ID: 10643536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin.
    Cormio G; Maneo A; Gabriele A; Zanetta G; Losa G; Lissoni A
    Am J Clin Oncol; 1997 Apr; 20(2):143-5. PubMed ID: 9124187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
    van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
    Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
    Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
    Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.
    Jelić S; Vuletić L; Milanović N; Tomasević Z; Kovcin V
    Tumori; 1990 Oct; 76(5):467-71. PubMed ID: 2256192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
    Koinumaru S; Matsuda T; Saitoh J; Nakai Y
    Lung Cancer; 1997 Nov; 18(3):241-51. PubMed ID: 9444649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.
    Jelić S; Kovcin V; Milanović N; Babović N; Kreacić M; Ristović Z; Vlajić M; Filipović-Ljesković I
    Eur J Cancer; 1997 Feb; 33(2):220-5. PubMed ID: 9135492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
    Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
    Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcoma.
    Jelić S; Babović N; Kreacić M; Matković S; Milanović N; Gavrilović D; Tomasević Z
    Int J Clin Pharmacol Res; 1999; 19(4):129-38. PubMed ID: 10939030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
    Specht L; Larsen SK; Hansen HS
    Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
    Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
    Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.